Cargando…

ASD and ADHD Comorbidity: What Are We Talking About?

According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hours, Camille, Recasens, Christophe, Baleyte, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918663/
https://www.ncbi.nlm.nih.gov/pubmed/35295773
http://dx.doi.org/10.3389/fpsyt.2022.837424
_version_ 1784668779299471360
author Hours, Camille
Recasens, Christophe
Baleyte, Jean-Marc
author_facet Hours, Camille
Recasens, Christophe
Baleyte, Jean-Marc
author_sort Hours, Camille
collection PubMed
description According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagnosis? Is ADHD in fact always present in such cases? Might the attentional impairment reported among our ASD patients actually be a distinct trait of their ASD—namely, impaired joint attention—rather than an ADHD attention deficit? Could their agitation be the consequence of this joint attention impairment or related to a physical restlessness etiologically very different from the agitation typical of ADHD? The neurobiological reality of ASD-ADHD comorbidity is a subject of debate, and amphetamine-based treatment can have paradoxical or undesirable effects in the ASD population. Consequently, does a dual diagnosis, notwithstanding its currency in the literature, prevent us from shedding sufficient light on major physiopathologic questions raised by the clinical picture of ASD?
format Online
Article
Text
id pubmed-8918663
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89186632022-03-15 ASD and ADHD Comorbidity: What Are We Talking About? Hours, Camille Recasens, Christophe Baleyte, Jean-Marc Front Psychiatry Psychiatry According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagnosis? Is ADHD in fact always present in such cases? Might the attentional impairment reported among our ASD patients actually be a distinct trait of their ASD—namely, impaired joint attention—rather than an ADHD attention deficit? Could their agitation be the consequence of this joint attention impairment or related to a physical restlessness etiologically very different from the agitation typical of ADHD? The neurobiological reality of ASD-ADHD comorbidity is a subject of debate, and amphetamine-based treatment can have paradoxical or undesirable effects in the ASD population. Consequently, does a dual diagnosis, notwithstanding its currency in the literature, prevent us from shedding sufficient light on major physiopathologic questions raised by the clinical picture of ASD? Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918663/ /pubmed/35295773 http://dx.doi.org/10.3389/fpsyt.2022.837424 Text en Copyright © 2022 Hours, Recasens and Baleyte. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Hours, Camille
Recasens, Christophe
Baleyte, Jean-Marc
ASD and ADHD Comorbidity: What Are We Talking About?
title ASD and ADHD Comorbidity: What Are We Talking About?
title_full ASD and ADHD Comorbidity: What Are We Talking About?
title_fullStr ASD and ADHD Comorbidity: What Are We Talking About?
title_full_unstemmed ASD and ADHD Comorbidity: What Are We Talking About?
title_short ASD and ADHD Comorbidity: What Are We Talking About?
title_sort asd and adhd comorbidity: what are we talking about?
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918663/
https://www.ncbi.nlm.nih.gov/pubmed/35295773
http://dx.doi.org/10.3389/fpsyt.2022.837424
work_keys_str_mv AT hourscamille asdandadhdcomorbiditywhatarewetalkingabout
AT recasenschristophe asdandadhdcomorbiditywhatarewetalkingabout
AT baleytejeanmarc asdandadhdcomorbiditywhatarewetalkingabout